State Street
BTAI icon

State Street’s BioXcel Therapeutics BTAI Stock Holding History

State Street’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Buy
92,118
+28,900
+46% +$47.6K ﹤0.01% 3991
2025
Q4 		$101K Buy
63,218
+10,500
+20% +$21.7K ﹤0.01% 4045
2025
Q3 		$135K Buy
+52,718
New +$166K ﹤0.01% 3995
2025
Q1 		– Sell
-4,822
Closed -$28.8K – 4288
2024
Q4 		$28.8K Hold
4,822
– – ﹤0.01% 4191
2024
Q3 		$47.1K Sell
4,822
-2,975
-38% -$40K ﹤0.01% 4112
2024
Q2 		$160K Sell
7,797
-21,260
-73% -$712K ﹤0.01% 3880
2024
Q1 		$1.31M Buy
29,057
+1,536
+6% +$73.3K ﹤0.01% 3400
2023
Q4 		$1.3M Buy
27,521
+1,905
+7% +$106K ﹤0.01% 3425
2023
Q3 		$1.04M Sell
25,616
-103,896
-80% -$10.5M ﹤0.01% 3522
2023
Q2 		$13.8M Buy
129,512
+19,469
+18% +$6.48M ﹤0.01% 2465
2023
Q1 		$32.9M Buy
110,043
+87,007
+378% +$37.2M ﹤0.01% 1911
2022
Q4 		$7.92M Sell
23,036
-69
-0.3% -$16.7K ﹤0.01% 2834
2022
Q3 		$4.37M Buy
23,105
+276
+1% +$64.1K ﹤0.01% 3132
2022
Q2 		$4.82M Sell
22,829
-64,718
-74% -$13.6M ﹤0.01% 3122
2022
Q1 		$29.3M Buy
87,547
+3,478
+4% +$1.01M ﹤0.01% 2125
2021
Q4 		$27.3M Buy
84,069
+1,032
+1% +$443K ﹤0.01% 2237
2021
Q3 		$40.3M Sell
83,037
-8,158
-9% -$3.59M ﹤0.01% 1969
2021
Q2 		$42.4M Buy
91,195
+11,451
+14% +$6.24M ﹤0.01% 1973
2021
Q1 		$55.1M Sell
79,744
-24,881
-24% -$20M ﹤0.01% 1672
2020
Q4 		$77.3M Buy
104,625
+23,759
+29% +$18.5M ﹤0.01% 1353
2020
Q3 		$56.1M Buy
80,866
+19,967
+33% +$15M ﹤0.01% 1372
2020
Q2 		$51.7M Buy
60,899
+53,012
+672% +$34.6M ﹤0.01% 1445
2020
Q1 		$2.82M Buy
7,887
+1,640
+26% +$589K ﹤0.01% 2905
2019
Q4 		$1.46M Buy
6,247
+946
+18% +$95.1K ﹤0.01% 3339
2019
Q3 		$597K Buy
5,301
+1,292
+32% +$204K ﹤0.01% 3478
2019
Q2 		$526K Buy
+4,009
New +$679K ﹤0.01% 3504

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street's BTAI Position: Q1 2026 in Review

State Street increased its BioXcel Therapeutics (BTAI) stake by 46% in Q1 2026, buying an estimated $47.6K and bringing the position to 92,118 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

State Street first reported a position in BTAI in Q2 2019 and has held it in 26 quarters since. The position peaked at $77.3M in Q4 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • State Street held 92,118 shares of BioXcel Therapeutics worth $123K as of Q1 2026.
  • State Street bought 28,900 BioXcel Therapeutics shares in Q1 2026, an estimated $47.6K.
  • BioXcel Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3991 holding.
  • State Street first reported a position in BioXcel Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • State Street's BioXcel Therapeutics position peaked at $77.3M in Q4 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.